BioMoti and CRO partner Pharmidex receive grant to advance cancer candidate

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/Alex011973)
(Image: Getty/Alex011973)

Related tags: Pharmacology

BioMoti and Pharmidex have received funding to advance proof-of-concept precision medicine studies – which if successful, could help secure pharma partnerships or additional investment, says BioMoti CEO.

BioMoti, Pharmidex, and Queen Mary University of London (QMUL) have been awarded a £662,222 ($879,497.04) grant by the UK’s innovation agency, Innovate UK, to support preclinical studies of new therapeutic approaches for hard-to-treat tumors.

Preclinical drug development services will be supported by Pharmidex, a contract research organization (CRO) that BioMoti has worked with over the past seven years, Dr. Davidson Ateh, BioMoti CEO told

The two-year program will focus on BMT101 – BioMoti’s lead Oncojan-based ovarian cancer candidate. The company describes Oncojans as a new class of therapeutic microparticles “that target and gain entry to the interior of cancer cells.​”

As part of the program, the companies will study immunomodulation and efficacy in immunocompetent models including HGSC (ovarian), TNBC (breast) and PDA (pancreatic), in addition to patient-derived xenograft models, biodistribution, pharmacokinetics and early toxicology.

The funding will also be used to advance pilot studies with undisclosed candidates and to establish a research-scale manufacturing facility. “These are key data sets that should be helpful to enable us to secure pharma partnerships or follow-on investment," ​Ateh explained.

Pharmidex also aims to develop its drug delivery technologies to help accelerate drug discovery and development processes, he said. “Successful studies could lead the way to co-marketing our platform as a research service to existing Pharmidex clients."

Related news

Show more

Related products

show more

Has EDC Kept Up With Changes In Clinical Trials?

Has EDC Kept Up With Changes In Clinical Trials?

Oracle Health Sciences | 14-Dec-2020 | Technical / White Paper

In just a few decades, clinical trials have changed dramatically. Twenty years ago, most of the data used in clinical research was entered on paper, but...

Related suppliers

Follow us


View more